Enveric Biosciences, Inc. (NASDAQ:ENVB) Short Interest Update

Enveric Biosciences, Inc. (NASDAQ:ENVB) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 330,200 shares, a growth of 70.9% from the October 15th total of 193,200 shares. Approximately 4.1% of the company’s shares are short sold. Based on an average daily volume of 486,400 shares, the days-to-cover ratio is currently 0.7 days.

Hedge Funds Weigh In On Enveric Biosciences

A hedge fund recently bought a new stake in Enveric Biosciences stock. Virtu Financial LLC bought a new position in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 33,835 shares of the company’s stock, valued at approximately $34,000. Virtu Financial LLC owned about 0.44% of Enveric Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 13.82% of the stock is owned by institutional investors and hedge funds.

Enveric Biosciences Stock Down 2.6 %

Shares of ENVB stock traded down $0.01 during trading hours on Thursday, hitting $0.40. 250,329 shares of the company were exchanged, compared to its average volume of 1,834,335. Enveric Biosciences has a 1 year low of $0.36 and a 1 year high of $2.92. The firm has a fifty day moving average of $0.47 and a 200 day moving average of $0.59. The firm has a market cap of $3.54 million, a PE ratio of -0.11 and a beta of 0.72.

Enveric Biosciences (NASDAQ:ENVB) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. Analysts expect that Enveric Biosciences will post -2.08 earnings per share for the current year.

About Enveric Biosciences

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.